These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38777812)

  • 1. Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST.
    Zheng D; Zhang Y; Yang S; Su N; Bakhoum M; Zhang G; Naderinezhad S; Mao Z; Wang Z; Zhou T; Li W
    Cell Death Discov; 2024 May; 10(1):246. PubMed ID: 38777812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST.
    Li W; Zheng D; Zhang Y; Yang S; Su N; Bakhoum M; Zhang G; Naderinezhad S; Mao Z; Wang Z; Zhou T
    Res Sq; 2023 Oct; ():. PubMed ID: 37886478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers.
    Zhang Y; Zheng D; Zhou T; Song H; Hulsurkar M; Su N; Liu Y; Wang Z; Shao L; Ittmann M; Gleave M; Han H; Xu F; Liao W; Wang H; Li W
    Nat Commun; 2018 Oct; 9(1):4080. PubMed ID: 30287808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel GRK3-HDAC2 regulatory pathway is a key direct link between neuroendocrine differentiation and angiogenesis in prostate cancer progression.
    Naderinezhad S; Zhang G; Wang Z; Zheng D; Hulsurkar M; Bakhoum M; Su N; Yang H; Shen T; Li W
    Cancer Lett; 2023 Sep; 571():216333. PubMed ID: 37543278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer.
    Chen WY; Thuy Dung PV; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Hsiao M; Huang J; Wen YC; Liu YN
    Redox Biol; 2023 Jun; 62():102686. PubMed ID: 36963289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of EHF facilitates the development of treatment-induced neuroendocrine prostate cancer.
    Long Z; Deng L; Li C; He Q; He Y; Hu X; Cai Y; Gan Y
    Cell Death Dis; 2021 Jan; 12(1):46. PubMed ID: 33414441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression.
    Wang Z; Zhao Y; An Z; Li W
    Front Oncol; 2019; 9():1491. PubMed ID: 32039001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.
    Enriquez C; Cancila V; Ferri R; Sulsenti R; Fischetti I; Milani M; Ostano P; Gregnanin I; Mello-Grand M; Berrino E; Bregni M; Renne G; Tripodo C; Colombo MP; Jachetti E
    Cancer Res; 2021 Aug; 81(16):4257-4274. PubMed ID: 34185677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-147b induces neuroendocrine differentiation of prostate cancer cells by targeting ribosomal protein RPS15A.
    Natani S; Ramakrishna M; Nallavolu T; Ummanni R
    Prostate; 2023 Jul; 83(10):936-949. PubMed ID: 37069746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of RACGAP1 by E2F1 Promotes Neuroendocrine Differentiation of Prostate Cancer by Stabilizing EZH2 Expression.
    Song Z; Cao Q; Guo B; Zhao Y; Li X; Lou N; Zhu C; Luo G; Peng S; Li G; Chen K; Wang Y; Ruan H; Guo Y
    Aging Dis; 2023 Oct; 14(5):1757-1774. PubMed ID: 37196108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of TGF-β - SMAD2 signaling by IL-6 drives neuroendocrine differentiation of prostate cancer through p38MAPK.
    Natani S; Sruthi KK; Asha SM; Khilar P; Lakshmi PSV; Ummanni R
    Cell Signal; 2022 Mar; 91():110240. PubMed ID: 34986386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
    Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-1205 Regulation of FRYL in Prostate Cancer.
    Naidoo M; Levine F; Gillot T; Orunmuyi AT; Olapade-Olaopa EO; Ali T; Krampis K; Pan C; Dorsaint P; Sboner A; Ogunwobi OO
    Front Cell Dev Biol; 2021; 9():647485. PubMed ID: 34386489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.
    Sang M; Hulsurkar M; Zhang X; Song H; Zheng D; Zhang Y; Li M; Xu J; Zhang S; Ittmann M; Li W
    Oncotarget; 2016 Jul; 7(29):45171-45185. PubMed ID: 27191986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling.
    Lin TP; Chang YT; Lee SY; Campbell M; Wang TC; Shen SH; Chung HJ; Chang YH; Chiu AW; Pan CC; Lin CH; Chu CY; Kung HJ; Cheng CY; Chang PC
    Oncotarget; 2016 May; 7(18):26137-51. PubMed ID: 27034167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation.
    Asberry AM; Liu S; Nam HS; Deng X; Wan J; Hu CD
    Comput Struct Biotechnol J; 2022; 20():5873-5885. PubMed ID: 36382181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. REST-repressed lncRNA LINC01801 induces neuroendocrine differentiation in prostate cancer via transcriptional activation of autophagy.
    Chang CH; Cheng TY; Yeh WW; Luo YL; Campbell M; Kuo TC; Shen TW; Hong YC; Tsai CH; Peng YC; Pan CC; Yang MH; Shih JC; Kung HJ; Huang WJ; Chang PC; Lin TP
    Am J Cancer Res; 2023; 13(9):3983-4002. PubMed ID: 37818052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment-induced neuroendocrine prostate cancer and
    Wishahi M
    World J Clin Cases; 2024 May; 12(13):2143-2146. PubMed ID: 38808339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
    O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
    Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate
    Zhou H; He Q; Li C; Alsharafi BLM; Deng L; Long Z; Gan Y
    Front Cell Dev Biol; 2022; 10():955669. PubMed ID: 35938167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.